Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fentanyl + flurbiprofen axetil is a combination analgesic therapy used primarily for postoperative pain management. Fentanyl is a potent synthetic opioid agonist at the mu-opioid receptor, providing strong analgesia and sedation. Flurbiprofen axetil is an injectable prodrug of the nonsteroidal anti-inflammatory drug (NSAID) flurbiprofen, which acts by inhibiting cyclooxygenase (COX) enzymes to reduce inflammation and pain. The combination has been shown to enhance analgesic effects compared to fentanyl alone, allowing for lower opioid doses and reducing opioid-related adverse effects such as nausea, dizziness, and lethargy. This synergy may be associated with increased endogenous β-endorphin levels postoperatively[1][5][7]. The combination is typically administered via intravenous infusion or patient-controlled analgesia in surgical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + flurbiprofen axetil.